Clinical Trials Browser

Phase 2 × Osteosarcoma × ridaforolimus × Clear all

NCT00093080 2015-02-13

Study of AP23573/MK-8669 (Ridaforolimus), A Mammalian Target of Rapamycin (mTOR) Inhibitor, in Participants With Advanced Sarcoma (MK-8669-018 AM1)(COMPLETED)

Phase 2 Completed

Leiomyosarcoma, Liposarcoma, Neoplasm Metastasis, Sarcoma, Osteosarcoma